Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. - Wikidata - wikimedia - TriplyDB

Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors.

Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors.

http://www.wikidata.org/entity/Q33387187

about

Evolving Therapies and FAK Inhibitors for the Treatment of Cancer Exome sequencing reveals a potential mutational trajectory and treatments for a specific pancreatic cancer patient.Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells Targeted therapies for gastric cancer: current status.Sequential combination therapy with flavopiridol and autocatalytic caspase-3 driven by amplified hTERT promoter synergistically suppresses human ovarian carcinoma growth in vitro and in mice.Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial.High-throughput RNAi screening of human kinases identifies predictors of clinical outcome in colorectal cancer patients treated with oxaliplatin.LARP7 is a potential tumor suppressor gene in gastric cancer.A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.Flavonoids, Flavonoid Subclasses, and Esophageal Cancer Risk: A Meta-Analysis of Epidemiologic Studies.Comparative drug screening in NUT midline carcinoma.Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors.The CDK inhibitors in cancer research and therapy.Emerging cell-cycle inhibitors for pancreatic cancer therapy.Recent advances and future trends in the targeted therapy of metastatic gastric cancer.Dinaciclib for the treatment of breast cancer.Highlights of the Latest Advances in Research on CDK Inhibitors.Cyclin-dependent kinase inhibitors and the treatment of gastrointestinal cancers.Emerging kinase inhibitors of the treatment of gastric cancer.Emerging Therapeutic Targets for Male Germ Cell Tumors.Investigational targeted therapies for the treatment of testicular germ cell tumors.Potential Use of Flavopiridol in Treatment of Chronic Diseases.

P2860

Q28972291-6F04AB03-EE9F-4AF6-99EB-89FE2B591873 Q33583509-3284E1C0-C4E3-4086-990A-AD4CCD2A1A16 Q34027454-BA344FF7-083C-42D2-888C-95A9AD4F88DE Q34205672-18C57677-00C0-49F2-86E8-4EF8D6837FB7 Q34997857-7CCEBCAE-43E8-41F2-BBA1-E2DB79ADC59E Q35034758-071F01B0-65EF-4800-BA8C-A4EB0B3674A3 Q35931388-3DAE4B40-BF0E-4251-9766-D920F8D95682 Q36140973-95177599-ECD8-4E87-BE5F-2BAD32DA756A Q36247023-758B7C41-E7A2-46F8-B768-22B02531C544 Q36363971-ECBDCA79-B5EC-4350-B0F7-CCDA3A8EBB1B Q37045133-CD32025C-223E-4BAA-BD35-2F046595B999 Q37632187-DC6E1D0F-B4AE-4024-B9B5-DC86C3BC0939 Q37798827-4C05E1AE-44AB-495F-904B-D0C7FEF04B11 Q37923861-8A519213-5D5E-4969-B1EC-F08168BC96CB Q38057759-7EE22508-95E5-49A1-B929-04F888B770D3 Q38199128-6EC8FE35-6BFE-4CFA-A62E-47DB42A85E9F Q38238282-460CD75E-B937-48AB-A5D8-3DD4D611B65B Q38263222-FA5C2680-E4FD-4CD9-A06D-F47AE0C59506 Q38369468-2FF6440E-2287-4DA4-8B89-57C0EA71D8A8 Q38506084-194A7635-9BBD-4B4D-BAB0-7F8D84CE54A6 Q38602699-402DC6FD-CD0D-4B0C-8137-D1732F6C63B1 Q38861307-5B749AC7-1B9E-4FAF-A441-A455D0D5C42B Q38988581-B6CDAA88-F3A8-4D21-B8C2-F6DDEC765DF0

P2860

Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors.

http://www.wikidata.org/entity/Q33387187

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase I study of flavopiridol ...... orin in advanced solid tumors.

@ast

Phase I study of flavopiridol ...... orin in advanced solid tumors.

@en

type

label

Phase I study of flavopiridol ...... orin in advanced solid tumors.

@ast

Phase I study of flavopiridol ...... orin in advanced solid tumors.

@en

prefLabel

Phase I study of flavopiridol ...... orin in advanced solid tumors.

@ast

Phase I study of flavopiridol ...... orin in advanced solid tumors.

@en

P1433

Q33387187-86B16646-9553-41C9-9958-4D8CE1DAF841

P1476

Q33387187-6F35151C-76BE-44D2-886B-C89069D1490A

P2093

Q33387187-0DC7D22C-BA41-4F24-BA43-BCA16901A1A4

Q33387187-115A62D3-BC2B-49CD-8546-853FD64004F7

Q33387187-4FE18F7B-3C23-4EF2-AEE8-F2756623B758

Q33387187-73761E98-8B6B-4297-9A08-F2622DEF07EF

Q33387187-7FA1B4D0-92B2-44FE-9EF9-6AF69666CBDF

Q33387187-9FB9AFDD-269A-4533-802F-7F3B6639DDD3

Q33387187-A1F21FF5-D2DB-4025-8B42-E39553767E7F

Q33387187-A58F962D-64E4-4022-901F-2CD5D4191F44

Q33387187-B9CA4F82-960A-4D7B-8F12-AD839D9EE510

P2860

Q33387187-00E1265B-E0D4-46EC-BAFF-462591989039

Q33387187-0B8FE222-ADF5-44A1-A570-97F05DE17047

Q33387187-162E4254-581B-4C3C-89CF-6A3670D9260D

Q33387187-22C45211-3031-4E7F-9290-091D3DE219E5

Q33387187-27AC96A1-935E-4046-8CD9-50D62A91606F

Q33387187-2B311F87-B97A-4FF6-B574-EED0C9052B74

Q33387187-3451859F-D359-443F-B553-CD4DE519CB15

Q33387187-41B25A6E-1CE1-419C-A5D7-CBA2EB739960

Q33387187-6FD1AB1F-C1FC-4C11-A2E3-026F9F8189D2

Q33387187-A96B784E-DECA-408F-A71E-CAC7EEA33B5B

P304

Q33387187-E5DE9A64-1982-4BD9-B087-A08E26A7271B

P31

Q33387187-E69A8E5F-3F73-4D5C-9A98-91AA31DC130D

P356

Q33387187-7157604E-6145-45DC-AEA3-B8153098D88A

P407

Q33387187-87E72FDD-3B05-490C-8C3B-776403975E82

P433

Q33387187-95E477EF-A090-4516-AEBB-595C3F948754

P478

Q33387187-2D58C94C-6FA0-438A-BB86-BA9465E06E82

P50

Q33387187-1F86091B-935C-4659-A6A0-D25EA6AC0ACD

Q33387187-27848EBA-C3A6-4F8A-8575-4255E986296D

Q33387187-28713C3B-A336-4FD8-8572-C9C085973F67

Q33387187-37A5D3FA-9069-4937-8441-A317B2851C8A

P577

Q33387187-AE4FD3A7-9C8E-4B35-823D-21F2AFA0C8F3

P698

Q33387187-4B3FEA5B-9DD8-4E37-926F-84F9D20EC318

P932

Q33387187-537025C7-9DF5-4FEA-8556-A8026C72B01B

P356

1078-0432.CCR-09-1502

P1433

Clinical Cancer Research

P1476

Phase I study of flavopiridol ...... orin in advanced solid tumors.

@en

P2093

Gary K Schwartz

http://www.w3.org/2001/XMLSchema#string

Heather J Dials

http://www.w3.org/2001/XMLSchema#string

Lauren M Cane

http://www.w3.org/2001/XMLSchema#string

Manish A Shah

http://www.w3.org/2001/XMLSchema#string

Mark A Dickson

http://www.w3.org/2001/XMLSchema#string

Mithat Gonen

http://www.w3.org/2001/XMLSchema#string

Nian Wu

http://www.w3.org/2001/XMLSchema#string

Richard D Carvajal

http://www.w3.org/2001/XMLSchema#string

Robert Lefkowitz

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells

Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group.

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Medical treatment of advanced testicular cancer.

Targeting the cell cycle: a new approach to cancer therapy.

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.

Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.

P304

7405-7411

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-1502

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Darren R Feldman

Jennifer L Winkelmann

Dana E Rathkopf

P577

2009-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19934304

http://www.w3.org/2001/XMLSchema#string

P932

2787644

http://www.w3.org/2001/XMLSchema#string